MCP
CLDX icon

Mirador Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

Mirador Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.74M Buy
181,054
+3,001
+2% +$96.9K 0.82% 31
2026
Q1 		$5.65M Buy
178,053
+7,394
+4% +$202K 0.8% 31
2025
Q4 		$4.64M Buy
170,659
+4,738
+3% +$125K 0.64% 40
2025
Q3 		$4.29M Buy
165,921
+7,204
+5% +$167K 0.61% 40
2025
Q2 		$3.23M Buy
158,717
+30,843
+24% +$600K 0.52% 41
2025
Q1 		$2.32M Buy
127,874
+8,382
+7% +$187K 0.41% 52
2024
Q4 		$3.02M Buy
119,492
+3,345
+3% +$90.9K 0.55% 42
2024
Q3 		$3.95M Buy
116,147
+3,768
+3% +$144K 0.71% 39
2024
Q2 		$4.16M Buy
112,379
+7,620
+7% +$288K 0.78% 34
2024
Q1 		$4.4M Sell
104,759
-3,151
-3% -$129K 0.84% 34
2023
Q4 		$4.28M Buy
107,910
+92
+0.1% +$2.71K 0.91% 28
2023
Q3 		$2.97M Buy
107,818
+3,103
+3% +$97.3K 0.68% 37
2023
Q2 		$3.55M Buy
104,715
+3,826
+4% +$129K 0.84% 34
2023
Q1 		$3.63M Sell
100,889
-4,669
-4% -$201K 0.86% 35
2022
Q4 		$4.7M Sell
105,558
-1,570
-1% -$56K 1.11% 24
2022
Q3 		$3.01M Buy
107,128
+760
+0.7% +$23.3K 0.73% 38
2022
Q2 		$2.87M Buy
106,368
+16,320
+18% +$474K 0.68% 43
2022
Q1 		$3.07M Buy
90,048
+3,996
+5% +$128K 0.62% 45
2021
Q4 		$3.33M Buy
86,052
+12,336
+17% +$538K 0.7% 44
2021
Q3 		$3.98M Sell
73,716
-4,963
-6% -$233K 0.9% 33
2021
Q2 		$2.63M Buy
78,679
+3,003
+4% +$82.4K 0.6% 51
2021
Q1 		$1.56M Buy
75,676
+48,927
+183% +$1.12M 0.4% 67
2020
Q4 		$469K Buy
26,749
+1,283
+5% +$23.1K 0.13% 118
2020
Q3 		$378K Buy
25,466
+6,332
+33% +$74.2K 0.12% 121
2020
Q2 		$249K Buy
19,134
+7,802
+69% +$34.6K 0.09% 134
2020
Q1 		$27K Buy
+11,332
New +$25.6K 0.01% 137

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Mirador Capital Partners's CLDX Position: Q2 2026 in Review

Mirador Capital Partners increased its Celldex Therapeutics (CLDX) stake by 1.7% in Q2 2026, buying an estimated $96.9K and bringing the position to 181,054 shares worth $6.74M. The position accounts for 0.82% of the portfolio, ranked #31.

Mirador Capital Partners first reported a position in CLDX in Q1 2020 and has held it in 26 quarters since. 16 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Mirador Capital Partners held 181,054 shares of Celldex Therapeutics worth $6.74M as of Q2 2026.
  • Mirador Capital Partners bought 3,001 Celldex Therapeutics shares in Q2 2026, an estimated $96.9K.
  • Celldex Therapeutics made up 0.82% of Mirador Capital Partners's portfolio in Q2 2026, its #31 holding.
  • Mirador Capital Partners first reported a position in Celldex Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 16 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.